On June 26, 2025, NLS Pharmaceutics Ltd. amended a Securities Purchase Agreement, raising $2 million through preferred shares and warrants, followed by an additional $1 million in financing from preferred participation certificates the next day. The company is offering these securities in accordance with Securities Act exemptions.